CG Oncology (CGON) EBITDA Margin (2023 - 2026)
CG Oncology (CGON) posted EBITDA Margin of 6130.1% for Q1 2026, down 192.28% on a QoQ basis from 2097.33% in Q4 2025, and up 7503144.0% year-over-year from N/an in Q1 2025.
CG Oncology (CGON) EBITDA Margin (2023 - 2026) Analysis & Trends
CG Oncology's EBITDA Margin history runs 4 years deep, the most recent figure standing at 6130.1% for Q1 2026.
- Quarterly EBITDA Margin rose 7503144.0% year-over-year to 6130.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4238.99% (up 1606328.0% YoY) and the FY2025 annual result came in at 4722.13%, up 534512.0% from the prior year.
- EBITDA Margin was 6130.1% for Q1 2026 at CG Oncology, down from 2097.33% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2097.33% in Q4 2025 and bottomed at 1935500.0% in Q4 2023.
- A 4-year average of 208244.27% and a median of 8344.08% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin surged 192715592 bps — and 2025, when it slumped 7691409 bps.
- CG Oncology's EBITDA Margin stood at 1935500.0% in 2023, then jumped by 100 bps to 8344.08% in 2024, then jumped by 75 bps to 2097.33% in 2025, then slumped by 192 bps to 6130.1% in 2026.
- Business Quant data shows CGON's EBITDA Margin at 6130.1% in Q1 2026, 2097.33% in Q4 2025, and 3068.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | CG Oncology | 5.86 Bn | 5.86 Bn | -1.88 Mn | -6,130.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,130.10% |
| Dec 31, 2025 | -2,097.33% |
| Sep 30, 2025 | -3,068.97% |
| Mar 31, 2025 | -81,161.54% |
| Dec 31, 2024 | -8,344.08% |
| Sep 30, 2024 | -65,802.33% |
| Jun 30, 2024 | -23,290.99% |
| Mar 31, 2024 | -4,247.45% |
| Dec 31, 2023 | -1,935,500.00% |
| Sep 30, 2023 | -156,033.33% |
| Mar 31, 2023 | -5,010.82% |